Muscular Atrophy

12 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Nervous System Diseases

Narrower: Sarcopenia 6

Treatments and conditions

Muscular Atrophy
Treatment and conditionWhere it standsTrials
AAV9-Follistatin gene therapy for sarcopeniaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AAV9-Follistatin gene therapy + VEGF Plasmid for sarcopeniaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apitegromab for muscular atrophyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Essential Amino Acid Supplementation for muscular atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MF-300 for sarcopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
OAV101 for muscular atrophyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Onasemnogene abeparvovec for muscular atrophyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Oxytocin for sarcopeniaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo Nasal Spray for sarcopeniaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Silkworm pupa tablets for sarcopeniaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total knee replacement for muscular atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Unicompartmental knee replacement for muscular atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.